Table 1.
Preliminary anti-psoriasis activity and cytotoxicities of thalidomide derivatives.
| Compounds | % Inhibition at 5 µM | % Viability | ||
|---|---|---|---|---|
| IL-6 | TNF-α | 5 µM | 10 µM | |
| Thalidomide (1) | 48.70 ± 1.10 | 22.97 ± 5.16 | 96.7 ± 3.4 | 86.7 ± 2.9 |
| 2a | 3.85 ± 1.66 | −2.45 ± 2.37 | 94.3 ± 2.5 | 86.0 ± 4.1 |
| 2b | 3.33 ± 0.44 | 5.67 ± 0.13 | 96.3 ± 2.1 | 91.7 ± 3.9 |
| 2c | 3.77 ± 0.56 | 12.93 ± 2.41 | 93.0 ± 4.3 | 94.7 ± 3.3 |
| 2d | 14.86 ± 3.20 | 30.38 ± 8.49 | 90.7 ± 2.1 | 89.7 ± 6.2 |
| 2e | 2.27 ± 1.66 | 39.77 ± 2.29 | 96.7 ± 2.1 | 84.0 ± 2.4 |
| 3b | 17.51 ± 6.41 | 12.69 ± 6.50 | 96.2 ± 3.5 | 89.8 ± 3.8 |
| 3c | 4.56 ± 2.91 | 8.28 ± 6.87 | 100.0 ± 0.3 | 98.1 ± 0.8 |
| 3e | 22.20 ± 0.27 | 11.39 ± 2.20 | 94.0 ± 3.6 | 89.3 ± 5.4 |
| 4a | 2.56 ± 0.52 | −5.21 ± 5.22 | 96.7 ± 2.1 | 93.0 ± 3.7 |
| 4b | 22.49 ± 1.90 | 0.28 ± 0.20 | 94.3 ± 2.9 | 93.3 ± 2.1 |
| 4c | 48.73 ± 2.25 | −1.32 ± 4.14 | 92.0 ± 4.5 | 93.7 ± 3.8 |
| 4d | 14.02 ± 8.97 | 12.59 ± 7.43 | 91.3 ± 3.3 | 91.3 ± 2.7 |
| 4e | 14.43 ± 0.68 | 5.01 ± 4.10 | 93.3 ± 0.5 | 88.0 ± 4.5 |
| 5b | 1.35 ± 0.18 | 2.89 ± 4.07 | 95.3 ± 3.3 | 95.0 ± 2.9 |
| 5c | 69.44 ± 4.39 | 75.01 ± 17.6 | 96.3 ± 2.5 | 90.3 ± 7.0 |
| 5e | 62.12 ± 3.22 | 3.17 ± 0.78 | 95.7 ± 4.0 | 66.3 ± 3.9 |
| 6b | 4.40 ± 1.61 | 34.46 ± 3.85 | 93.7 ± 3.1 | 90.3 ± 2.5 |
| 6c | 3.19 ± 0.80 | 7.35 ± 1.07 | 91.0 ± 2.4 | 58.7 ± 6.1 |
| 6e | 2.09 ± 1.86 | 2.19 ± 6.51 | 98.0 ± 1.6 | 97.0 ± 2.2 |
Results are presented as mean ± standard deviation (n = 3).